SDP-LIV1

SDP-LIV1 is a novel antibody-drug conjugate (ADC) designed to target LIV-1 (SLC39A6), a transmembrane zinc transporter protein frequently overexpressed in various solid tumors, including breast and gastric cancers. Developed by Jiangsu Hengrui Pharmaceutical, SDP-LIV1 consists of a humanized anti-LIV-1 monoclonal antibody conjugated to a proprietary topoisomerase I inhibitor payload via a cleavable glycine-glycine-phenylalanine-glycine (GGFG) linker. The conjugate features an optimized average drug-to-antibody ratio (DAR) of 6. SDP-LIV1 was engineered to improve upon the efficacy and safety profile of earlier LIV-1-targeting ADCs, such as ladiratuzumab vedotin, by utilizing a different payload class and linker chemistry. Preclinical studies have demonstrated superior antitumor activity and a favorable safety profile in solid tumor models, suggesting potential for clinical treatment of LIV-1-expressing malignancies.